. Author manuscript; available in PMC: 2014 Dec 1.

Published in final edited form as: Infect Genet Evol. 2013 Aug 17;20:78–82. doi: 10.1016/j.meegid.2013.08.008

Table 3.

Uni- and multivariate analyses between HIV status and co-variates among HIV positive IDUs and HESNs.

Co-variate	Outcome: HIV positivity OR (95% CI; p-value)
Co-variate	Outcome: HIV positivity OR (95% CI; p-value)	Univariate analyses
TLR3 rs3775291
Non-T allele^a	1.0
T allele	0.29 (0.09–0.90, 0.03)
Age
Years^b	1.03 (0.94–1.13, 0.51)
Gender
Male^a	1.0
Female	0.88 (0.30–2.57; 0.81)
HCV serostatus
HCV−^a	1.0
HCV+	14.08 (2.89–68.53; <0.01)
HBV serostatus
HBV−^a	1.0
HBV+	6.09 (2.02–18.36; <0.01)
Duration of intravenous drug use Years^b	1.12 (1.01–1.24; 0.02)
Multivariate analyses
TLR3 rs3775291
Non-T allele^a	1.0
T allele	0.25 (0.07–0.87; 0.03)
HCV serostatus
HCV−^a	1.0
HCV+	15.35 (2.46–95.69; <0.01)
HBV serostatus
HBV−^a	1.0
HBV+	1.25 (0.50–3.11; 0.63)
Duration of intravenous drug use Years^b	1.11 (1.00–1.23; 0.06)

Note: OR, odds ratio; CI, confidence interval.

Reference group.

Years were categorized as a continuous variable in full-years, and data reflects an increase in OR with each additional year of age or intravenous drug use.